期刊
SCIENCE
卷 354, 期 6308, 页码 69-73出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aaf5094
关键词
-
资金
- Wellcome Trust [098381]
- European Commission [HEALTH-F4-2007-201413, CoG-2015_681742_NASCENT, IMI_JU_2010_DIRECT, IMI_JU_2016_RHAPSODY]
- Medical Research Council [MR/L020149/1, MR/M004422/1]
- National Institutes of Health [DK098032, DK105535]
- Swedish Research Council (Distinguished Young Researchers Award in Medicine)
- Swedish Heart-Lung Foundation
- Swedish Diabetes Association
- European Foundation for the Study of Diabetes
- Novo Nordisk Foundation
- Pfizer
- Roche
- Novo Nordisk
- Eli Lilly
- AstraZeneca
- Sanofi Aventis
- Johnson Johnson
- Servier
- Takeda
- Boehringer Ingelheim
- European Foundation for the Study of Diabetes [MSD 2015_2] Funding Source: researchfish
- Medical Research Council [MR/L020149/1, MR/M004422/1] Funding Source: researchfish
- MRC [MR/M004422/1, MR/L020149/1] Funding Source: UKRI
The rising prevalences of type 2 diabetes and obesity constitutemajor threats to human health globally. Powerful social and economic factors influence the distribution of these diseases among and within populations. These factors act on a substrate of individual predisposition derived from the composite effects of inherited DNA variation and a range of environmental exposures experienced throughout the life course. Although Western lifestyle represents a convenient catch-all culprit for such exposures, effective treatment and prevention will be informed by characterization of the most critical, causal environmental factors. In this Review, we examine how burgeoning understanding of the genetic basis of type 2 diabetes and obesity can highlight nongenetic exposures that drive development of these conditions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据